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Summary 
Interleukin-1 [3  (IL-l[3)-converting enzyme (ICE) is a novel cysteine protease that cleaves the 
31-kD inactive cytoplasmic IL-113 precursor into active extracellular 17-kD  IL-113. The ICE 
gene product is a 45-kD proenzyme that requires proteolytic processing to activate ICE. Active 
ICE is a heterodimer consisting of equal amounts of p20 and p l0 subunits.  Generation of ac- 
tive ICE is affected by the removal of an 11-kD NH2-terminal precursor domain (pl 1) and an 
internal 19-amino acid sequence that separates the 20- and 10-kD subunits. Immuno-electron 
microscopy was performed on human monocytes with immunoglobulins recognizing the ac- 
tive (p20)  or precursor (p11) domains of ICE. Elutriated monocytes were stimulated with 50 
pM lipopolysaccharide followed by heat-killed  Staphylococcus  aureus under conditions  that in- 
duce maximal rates of IL-113 secretion. Ultrathin cryosections were cut from fixed frozen pel- 
lets of these monocytes and were immunogold labeled with either antibody. Active and pre- 
cursor domain ICE epitopes were localized in the cytoplasmic ground substance, but they were 
not detected within the endoplasmic reticulum, the Golgi apparatus, and secretory granules of 
activated or inactive monocytes. Importantly, numerous ICE p20 epitopes were also observed 
on the extracellular surfaces of the cell membrane, and were concentrated  on the microvilli. 
Very similar patterns of ICE localization were obtained with unstimulated blood monocytes. In 
contrast, ICE pl I  epitopes were not detected on the surfaces of these rnonocytes. Likewise, la- 
beling of fixed ultrathin cryosections ofmonocytes with a biotinylated irreversible ICE inhibi- 
tor [Ac-Tyr-Val-Lys(biotin)-Asp-(acyloxy)-methyl-ketone] showed that the compound local- 
ized on the  outer cell surface as well,  and to a lesser extent,  within  the  cytoplasmic ground 
substance.  Furthermore, antipeptide antibodies specific for either the mature or precursor do- 
mains of IL-113 were both localized upon the cell membrane after stimulation of IL-113 secre- 
tion. Lipopolysaccaride-primed monocytes that synthesized, but did not secrete IL-113, exhib- 
ited only cytoplasmic staining. The data suggests that mature IL-l[3 is generated via cleavage of 
the  31-kD  inactive  cytoplasmic  IL-lJ3  precursor  by  ICE  after association  with  the  plasma 
membrane during secretion. 
I 
L-I[3 is  a  pleiotropic  proinflarnmatory cytokine  that  is 
primarily  secreted  by  activated  monocytes  or  macro- 
phages. While  the biological effects of IL-113 are well de- 
scribed,  little  is known  about the  detailed mechanism re- 
sponsible  for  IL-113  processing  and  secretion.  Synthesis, 
processing, and secretion of IL-113 occurs through  a well- 
orchestrated, tightly regulated sequence of events. In mono- 
cytes, IL-113 is synthesized in response to a wide variety of 
stimulants,  the  most potent  being LPS  or  other bacterial 
cell wall products.  IL-113 is first synthesized in monocytes 
as an inactive 31-kD precursor (prolL-1 [3) 1 (1, 2). ProlL-113 
lacks a definable signal sequence, is synthesized on cytosolic 
polyribosomes, and  has been localized to  the  cytoplasmic 
ground  substance  outside  of the  ER  by immmuno-elec- 
tron microscopy (immunoEM; 3, 4). 
1Abbreviations used in this paper: ElL, endoplasmic  reticulum; HKSA, heat- 
killed Staphylococcus aureus; ICE, interleukin-l-converting enzyme; im- 
munoEM, immuno-electron  microscopy;  L-709,049, unlabeled reversible 
ICE inhibitor; L-742,395, biotinyl-irreversible  ICE inhibitor; L-743,066, 
nonbiotinylated irreversible ICE inhibitor; prolL-l[3, inactive 31-kD IL- 
l [3 precursor; ProlCE, 45-kD proenzyme  ICE gene product. 
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the  active  17.5-kD  IL-113  occurs  through  an  ill-defined 
pathway. Pulse-chase analysis suggests that the cleavage and 
secretion  of IL-113  occurs  in  a  cotemporal  manner  (5). 
ProlL-1]3 is cleaved between residues Asp  116 and Ala 117 by 
the protease  IL-l-converting enzyme (ICE)  (6,  7)  to gen- 
erate active IL-113.  Active ICE has been purified from hu- 
man  monocytes  and  identified  as  a  novel  heterodimeric 
thiol  protease  composed  of two  subunits,  p20  and  pl0. 
Mature  ICE  (p20/pl0)  is  derived  from  a  single  45-kD 
proenzyme (I045 ICE) by proteolysis  at  ICE-like cleavage 
sites,  resulting  in the  excision  of an  11-kD  NH2-terminal 
precursor domain  (p11)  and  a  2-kD  linker  separating  the 
20- and 10-kD subunits  (8-11). Unlike IL-113,  ICE is pro- 
duced constitutively by human blood monocytes. Subcel- 
lular  fractionation  of human monocytes has  detected  ICE 
activity and the p45  ICE proenzyme predominantly in the 
cytosolic fraction (7,  12). 
A  tetrapeptide  aldehyde  inhibitor  of ICE  that  blocks 
production  of mature  IL-113  from LPS-stimulated  human 
blood  monocytes  has  been  described  (11).  Treatment  of 
LPS-stimulated  monocytes with  this  inhibitor  results  in  a 
specific dose-dependent inhibition  (ICs0  =  1 p,M)  of IL-113 
processing.  Despite  inhibition  of processing,  IL-113  secre- 
tion  remains  unaffected.  Instead,  a  quantitative  shift  from 
secretion  of mature  IL-113  to  release  of prolL-1]3  occurs, 
suggesting that prolL-l[3 processing is not required for, but 
is  cotemporal  with,  the  secretion  of mature  IL-113  (11). 
Furthermore,  this  observation  suggests  that  prolL-1]3  is  a 
secretion-competent form of IL-113. 
The  biochemical  detection  of both  the  45-kD  proen- 
zyme  ICE  gene  product  (prolCE)  and  prolL-1]3  in  the 
cytosol raises  the  question  of how these  two  proteins  are 
mobilized to generate mature extracellular IL-113.  One hy- 
pothesis  is  that  events  leading  to  apoptosis  are  primary 
mechanisms  of  IL-113  secretion  (13,  14).  Treatment  of 
LPS-stimulated murine macrophages with agents that cause 
apoptosis lead to the release of large amounts of mature IL- 
l ]3.  Conditions  resulting  in necrosis lead to the  release  of 
prolL-1[3 or improperly processed IL-113  (13).  These  ob- 
servations  imply  that  apoptosis-related  processes  such  as 
plasma  membrane  vesiculation  and  blebbing  may lead  to 
release of mature IL-113. 
We  have  performed  high  resolution  immunoEM  with 
immunoprobes  of precursor  and  mature  ICE  and  IL-113 
epitopes,  as well as with  a novel ICE active site  detection 
method,  to further  characterize  the  IL-113  secretory path- 
way in human blood monocytes. We show that processed 
active ICE is localized on the external surfaces of the intact 
plasma  membrane  in  stimulated  and  unstimulated  human 
monocytes. Both mature and prolL-l[3 are also detected on 
external surfaces of the plasma membrane,  which does not 
exhibit observable blebbing during conditions of rapid IL- 
113 secretion  in stimulated  monocytes. These  observations 
indicate  that  prolL-1]3  is  proteolytically processed  during 
transport across the plasma membrane in the absence ofap- 
optosis. 
Materials and Methods 
Antibodies.  Rabbit  antibodies  (JD3)  were  raised  against  the 
catalytic domains (p20/pl0) of mature ICE purified  from THP-1 
cells (a cultured human monocyte line), and to the NH2-terminal 
amino acid sequence 34-47 (I34-47)  ofprolCE (12). A rabbit an- 
tibody that specifically detects amino acids 3-21 of prolL-l [3 (15) 
was a generous gift of Dr. Mark D. Wewers (Dept.  of Medicine, 
Ohio State University, Columbus, OH). Rabbit antipeptide  anti- 
bodies  specific  for  the  COOH-terminal  amino  acid  sequence 
197-215  of mature  IL-113 were used as previously described  (1, 
3). For immunoEM experiments,  IgG fractions of the above anti- 
sera were  purified  by chromatography on protein  A-Sepharose 
(Pharmacia  Fine Chemicals,  Piscataway,  NJ).  Rabbit antipeptide 
antibodies  recognizing the  ICE-generated cleavage  fragment of 
prolL-113 containing a COOH-terminal Asp 1  u, were prepared to 
the  peptide  Cys-Nle-Asp-Thr-Asp-Asn-Glu-Ala-Tyr-Val-His- 
Asp-COOH as previously described  (1). Antisera were character- 
ized for their ability to recognize the immunizing peptide by di- 
rect ELISA in peptide  coated 96-well microtiter plates.  Positive 
antisera were then counterscreened for their ability  to recognize 
prolL-l[3,  ICE-cleaved prolL-l[3,  or mature  IL-1[3. Antiserum 
502T was chosen for its ability to react with the cleaved prolL-1[~ 
with  >100-fold more sensitivity  than uncleaved prolL-l[3 in  a 
direct ELISA. Selectivity  of the  antiserum was  further  demon- 
strated by showing that 502T could not detect prolL-l[3 or ma- 
ture  IL-1~3 by  immunoprecipitation  and  by  Western  blotting 
(data not shown), 
Cells.  An  enriched  population  of PBMC  was  obtained  by 
leukophoresis  from healthy human volunteers.  PBMC were puri- 
fied by density  gradient  centrifugation over Ficoll-Hypaque fol- 
lowed by centrifugal  elutriation  as previously described  (7,  16, 
17).  Approximately  5  X  108  monocytes  of >95%  purity  as 
judged by size distribution  analysis were obtained with this proto- 
col.  After elutriation,  the purified blood monocytes were resus- 
pended to 5 ￿  10  s cells/ml in 1KPMI containing l% fresh autolo- 
gous  human  serum  and  stimulated  for 3-6  h  with  heat-killed 
Staphylococcus aureus (HKSA; 106 CFU/10 s monocytes per ml) as 
described  previously (16). To obtain maximal  rates of cytokine 
secretion  for IL-l[3-1abeling experiments,  elutriated  human blood 
monocytes were primed for 4 h in medium with 50 pg/ml LPS, 
and IL-1 [3 secretion was stimulated  by treatment with HKSA for 
2 h (16). The extent of IL-1[3 secretion into the culture medium 
was assessed by ELISA. 
ImmunoEM Labeling of ICE Epitopes.  After stimulation,  puri- 
fied  monocytes were fixed in a solution of 3.5% paraformalde- 
hyde, 0.05% glutaraldehyde,  and 0.1  M  sucrose in PBS, pH 7.4, 
in the presence of microwave irradiation,  followed by overnight 
fixation  with a mixture  of paraformaldehyde,  lysine,  and perio- 
date  (18,  19). Pellets  of fixed  monocytes were infiltrated  in 2% 
low  gelling  temperature  agarose,  cryoprotected  by  infiltration 
with 2.3 M  sucrose  and 50% polyvinylpyrrolidone in phosphate 
buffer,  pH 7.2  (20), frozen by injection  into liquid propane  at 
-185~  in a KF-80 apparatus  (1Keichert Scientific  Instruments, 
Buffalo, NY), and stored under liquid nitrogen. To permit access 
of antibodies  or ICE probes (see below) to all sectioned subcellu- 
lar compartments, ultrathin  (-,~80-nm) frozen sections were cut at 
-105~  (21) on a Reichert Ultracut S ultramicrotome equipped 
with an FCS cryoattachment, and transferred  to fonnvar-coated 
200  mesh hexagonal  nickel  grids.  Sections  were treated  with  a 
clarified solution of 5% nonfat dry milk and BSA buffer (1% BSA 
in PBS, pH 7.8,  containing 0.1% Na azide) for 30 rain to block 
nonspecific  binding,  followed by overnight incubation in 5 p,g/ 
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4~  For specificity controls,  5  Ixg/ml JD3  IgG  was  absorbed 
with 250 ~g/ml purified recombinant human ICE, and 5 Ixg/ml 
I34-47 IgG was absorbed with 3 mg/ml of the peptide used for 
immunization and was clarified by centrifugation before immu- 
nolabeling. Other controls consisted of 5 I.Lg/ml solutions of the 
respective preimmune rabbit IgGs in BSA buffer. After extensive 
washing in  PBS,  the bound primary rabbit IgGs were  detected 
with a goat anti-rabbit 5-nm colloidal gold conjugate (GARG 5; 
Amersham Corp.,  Arlington Heights,  IL)  diluted  1/50  in BSA 
buffer for 1 h  at 23~  The grids were then washed in PBS and 
fixed in 2%  glutaraldehyde in PBS for 10  rain, postfixed in 2% 
OsO4 in H20 for 20 rain, stained with 2% uranyl acetate in H20 
for 30 min, and finally absorption stained with 0.002% lead citrate 
in 2% polyvinyl alcohol as described (21).  Grids were examined 
and  electron micrographs were  taken  with  an  electron micro- 
scope  (200CX; Jeol Ltd.,  Tokyo, Japan)  at  80  kV  at an  initial 
magnification of 20,000. 
ImmunoEM Labeling of the ICE Active Site.  For  direct labeling 
of the ICE active site, intact living resting or activated monocytes 
were treated with 50 nM-20 txM biotinyl-irreversible  ICE inhib- 
itor  L-742,395  [Ac-Tyr-Val-Lys(biotin)-Asp-(acyloxy)-methyl- 
ketone] (22) for 0.5 to 6 h before fixation, washed, and prepared 
for immunoEM as described above. For controls, other cell cul- 
tures were incubated with 20  IxM L-743,066,  a  nonbiotinylated 
but otherwise identical irreversible ICE inhibitor (22).  Ultrathin 
frozen sections of these cells were then cut, and the incorporated 
biotinyl  L-742,395  was  detected  using  sequential  incubations 
with 5 Ixg/ml avidin-DN (Vector Laboratories, Burlingame, CA) 
in BSA buffer, a biotinyl afffinity-purified  goat antiavidin antibody 
(Vector Laboratories), and a rabbit anti-goat IgG 5 nm colloidal 
gold conjugate (RAGG5; Amersham). In an alternative approach 
to  enhance  the access  of the labeled probe to  intracellular ICE 
sites, thin sections of fixed cells were stained direcdy with bioti- 
nylated irreversible ICE inhibitor. To protect the ICE active site 
from  excessive denaturation, human  monocytes were  activated 
(6 h  with HKSA) in 50  I.~M unlabeled reversible ICE inhibitor 
L-709,049,  then  fixed, washed,  and  prepared for  immunoEM. 
Grids containing ultrathin cryosections of these cells were  then 
incubated with serial dilutions of L-742,395  in PBS, and stained 
with avidin-DN, goat antiavidin antibody, and RAGG5  as de- 
scribed above. To monitor the specificity of this staining protocol, 
other grids were treated with a 400-fold molar excess of unlabeled 
reversible ICE inhibitor L-709,049  or the unlabeled L-743,066 
before and during incubation with the biotinylated inhibitor. In 
another control, BSA buffer was  substituted for the avidin-DN 
step of the biotin detection protocol. 
Labeling of  Mature and Prodomain  IL-l  fl Epitopes.  Monocytes were 
elutriated from human blood and then primed for 4 h in medium 
with 50 pg/ml LPS. A high rate of IL-113 secretion was initiated 
by stimulation with HKSA for an additional 2  h. After pelleting 
and processing for immunoEM, ultrathin frozen sections of either 
primed  or  stimulated monocytes  were  labeled with  antibodies 
that distinguish the prodomain from the mature form of IL-113. 
Grids were  incubated with  a  rabbit IgG directed against amino 
acid residues  197-215  of mature  IL-113, or with another rabbit 
IgG  recognizing amino  acid residues 3-21  of IL-113 precursor, 
followed by a GARG5 as detailed above. As a control, the mature 
IL-113 IgG was absorbed with a  1.5  mg/ml solution of purified 
recombinant human IL-113 in BSA buffer before staining. 
Results 
Characterization of  Antibodies.  Active ICE (p20/pl0) is de- 
rived by proteolytic cleavage of the  11-kD  propiece (pl 1) 
and  a  2-kD  linker  from  the  inactive  45-kD  proenzyme 
(p45).  A  polyclonal antibody raised against purified active 
human  ICE  (JD3)  recognizes  epitopes located in  a  single 
p20  band  in  immunoblots  of affinity-purified active  ICE 
(Fig.  1).  Conversely,  another  antipeptide polyclonal anti- 
body raised to amino acid residues 34-47  of the ICE pro- 
piece  (I34-47)  does  not  react with  affinity-purified active 
ICE.  Both JD3  and 134-47  IgG label p45  in immunoblots 
of crude  whole  cell extracts from  stimulated or unstimu- 
lated human blood monocytes and THP.1  cells, while the 
p20 subunit is not detectable (Fig. 1). 
ImmunoEM Localization  of Active ICE and ProlCE Epi- 
topes.  When  ultrathin  cryosections  of HKSA-stimulated 
monocytes were labeled with JD3  IgG, ICE epitopes were 
localized at the extracellular surfaces of the cell membrane 
surrounding  numerous  elongate microvilli, ruffling lamel- 
lae,  and  large  (~0.2-1  I~m diameter)  pinocytotic vesicles 
present at the cell surface (Fig. 2 A). ICE was also observed 
in the cytoplasmic ground substance, while organelles such 
as the ElL, secretory granules, the nuclear envelope, mito- 
chondria,  and the nucleus proper were not labeled (Fig. 2 
B). ICE labeling was completely inhibited by preincubating 
5  Ixg/ml JD3  IgG  with  250  I~g/ml  purified  rhlCE  (not 
shown),  and preimmune  rabbit IgG produced little back- 
ground  (Fig. 2  C).  Thus,  ICE  epitopes, representing both 
precursor (p45)  and active (p20)  ICE,  were localized spe- 
cifically on  the  cell surface  and in  the  cytoplasmic matrix 
exclusive of the  conventional secretory organelles in  acti- 
vated  monocytes.  Cell  culture  supernatants  from  these 
stimulated cells contained significant amounts  of IL-1I~ as 
detected by ELISA (Table I), indicating that active ICE was 
present in these cells. It is also noteworthy that these IL-113 
secreting monocytes exhibited completely intact cell mere- 
Figure  1.  Immunoblots demonstrating the  specificity of the JD3  and 
I34-47 antibodies for the ICE domains expressed by human monocytic 
cells. Crude  whole-cell  extracts of stimulated or  unstimulated human 
monocytes, PMA-differentiated THP.1 cells, and affinity-purified  human 
ICE  (AP) were immunoblotted  and stained with JD3  and I34-47 IgGs. 
Arrows indicate the positions of inactive prolCE (p45), and the compo- 
nents of active ICE (p22, p20, and plO). JD3 and I34-47 antibodies rec- 
ognize inactive prolCE found in all crude cell extracts. Only JD3  IgG 
stains the active p20 subunit of affinity-purified  ICE, which is not detect- 
able in the cell extracts. 
1449  Singer et al. Figure  2.  Immunoelectron micrographs of ultrathin cryosections of HKSA-stimulated human monocytes labeled with JD3  lgG.  (A)  ICE labeling is 
present on the external surfaces of the cell membrane (arrowheads; arrows depict the intact continuous hpid bilayer), and it is concentrated particularly on 
microvilli (M) and lamellae (L). Microvilli at left appear to be engaged in the formation of an intracytoplasmic vacuole with ICE-positive internal mem- 
branes (V). ICE epitopes are also found in the ground substance of the cytoplasm (crossed arrows), but they are excluded from the nucleus (N). No signs of 
apoptosis (cell surface blebbing and nuclear condensation) are evident. (B) Preparation similar to A  depicting ICE JD3 epitopes localized on the external 
surfaces of the cell membrane (arrowheads) and within the cytoplasmic ground substance (arrow). Secretory organelles such as the ER, vacuoles (V),  and 
dense granules (G) are not labeled. (C) Ultrathin cryosection of an HKSA-stimulated monocyte stained with preimmune lgG. No immunostaining is ob- 
served on the microvilli (M),  the cell membrane (arrowheads), or within the cytoplasm. Bars for A  and B, 0.2 p,m; C, 0.4 ~m. 
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Monocytes 
Percent 
Stimulus*  ICE inhibitor*  IL-II3 secretion  ~  inhibition 
ng /ml 
HKSA  RPMI  5.87  0 
HKSA  L-709,049  1.63  72 
HKSA  L-743,066  1.39  76 
HKSA  L-742,395  1.88  68 
HKSAII  50 nM L-742,395  2.96  0 
HKSAII  18 I.tM L-742,395  0.75  75 
*Elutriated human monocytes (5 ￿  10S/ml)  were  stimulated with  106 
CFU/ml of HKSA for 6 h. No IL-1[3 secretion was detected in com- 
panion cultures that were mock-stimulated with P,  PMI in the presence 
of 15 la,  M  L-709,049, L-743,066, L-742,395, or medium alone. 
*Cells were treated with 15 p~M ICE inhibitor added to their media at 
the beginning of stimulation. 
w  IL-113 was detected in culture supematants by ELISA after 6 h of stim- 
ulation. 
IIIn a  separate experiment, elutriated monocytes were stimulated with 
HKSA for 3 h and then treated with the indicated concentrations ofbi- 
otinyl-lCE inhibitor for 30 min. 
branes and lacked evidence ofapoptosis such as cell-surface 
blebbing and pycnotic nuclei (Fig. 2, A and B). 
In  unstimulated peripheral blood monocytes, JD3  ICE 
epitopes were similarly localized on external surfaces of the 
cell membrane (especially on microvilli and in pinocytotic 
vesicles;  Fig.  3, A  and  B)  and in  the  cytoplasmic ground 
substance outside of the ElL (Fig.  3 B). Since their culture 
media lacked detectable IL-113 (Table  1), these cells were 
not inadvertently activated. Very similar immunoEM pat- 
terns of ICE localization were also observed in the unstim- 
ulated human monocytic line THP. 1 (data not shown). To 
ensure that significant numbers of unstimulated monocytes 
were positive for ICE, labeling was also assessed using im- 
munofluorescent  microscopy.  Positive  ICE  staining  was 
observed in  most  monocytes  (>95%)  of either unstimu- 
lated or stimulated  cultures  (Table 2).  While most of the 
cells in the unstimulated cultures were IL-113 negative, 98% 
of the stimulated ceils  stained positive for IL-113. Collec- 
tively, these results  strongly suggest that ICE  is  expressed 
constituitively upon the  cell surface and within  the  cyto- 
plasm  of both  unstimulated  and  activated human  mono- 
cytes. 
Since the JD3  antibody detects both p20 and p45  ICE, 
parallel experiments were conducted with the anti-prolCE 
antibody (134-47)  to distinguish prolCE from mature ICE 
in activated and unstimulated monocytes. Anti-I34-47 IgG 
stained the cytoplasmic ground substance outside of the ElL 
and nuclear envelope, but in striking contrast to JD3,  did 
not label the  external surfaces  of the  cell membrane,  mi- 
crovilli,  and  pinocytotic  vesicles  (Fig.  3  C).  These  data 
show  that  proICE  epitopes  are  not  detected on  the  cell 
membrane  and  imply  that  the  ICE  propiece is  lost after 
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ICE maturation (formation ofp20/pl0 ICE) at the cell sur- 
face. 
Active-site  EM Labeling  of ICE with a Biotinylated Inhibitor. 
To confirm the immunoEM localization of ICE  epitopes 
described above, we developed a highly sensitive method 
to label the active site of ICE in human monocytes. Intact 
HKSA-stimulated  or  resting  monocytes  were  incubated 
with 15-18 ~M ofa biotinylated acyloxymethyl ketone (an 
irreversible inhibitor of ICE, L-742,395  [22]),  resulting in 
68-75%  inhibition  of IL-115 secretion  by  the  activated 
monocytes (Table 1). Similar levels of inhibition were ob- 
served with non-biotinyl-acyloxymethyl  ketone (L-743,066) 
or with  the  reversible aldehyde ICE  inhibitor L-709,049 
(Table  1),  confirming the  observation  that  biotinylation 
does not diminish the potency of the ICE inhibitor, Com- 
pound-treated monocytes were washed, fixed, cryosectioned, 
and  L-742,395  detected  with  the  avidin-immunogold 
amplification method.  Using  intact monocytes prelabeled 
with micromolar concentrations ofL-742,395, biotinylated 
compound was  concentrated on the  extracellular surfaces 
of the cell membrane, microvilli, and pinocytotic vesicles, 
and was also observed in the cytoplasmic ground substance 
(Fig.  4  A).  Similar results  were obtained with nonstimu- 
lated  monocytes incubated with  L-742,395  (not shown). 
These patterns  are strikingly similar to the distribution of 
ICE protein, as determined with antibody JD3.  This sug- 
gests that the biotinylated compound is labeling the active 
site  of ICE  in  intact monocytes. No  signal  was  detected 
when  HKSA-stimulated  monocytes  were  preincubated 
with 50 nM L-742,395, a concentration which did not in- 
hibit  production  of mature  IL-113 (Table  1),  or  when 
monocytes  were  treated  with  micromolar  quantities  of 
nonbiotinylated ICE inhibitors (data not shown). 
In striking contrast to the intact cell,  active site labeling 
was  observed at  "q,000-fold lower inhibitor  concentra- 
tions if the compound was applied to ultrathin cryosections 
of stimulated  monocytes. When  5-500  nM  quantities  of 
L-742,395 were applied to the sectioned monocytes, ICE 
active-site staining was again observed on the external sur- 
rices of  the cell membrane and within the cytoplasmic ground 
substance,  but was absent from the Elk and nuclear envelope 
(Fig.  4,  B and  C).  This labeling was blocked by pretreat- 
ment  with  either the  reversible ICE  inhibitor L-709,049 
(Fig.  4 D)  or with the nonbiotinylated acyloxymethyl ke- 
tone  (L-743,066);  very  little  background  was  obtained 
when  the  sections  were  incubated  with  L-743,066  fol- 
lowed  by the  avidin-amplification  reagents  (not  shown). 
These results are therefore highly specific for localization of 
active ICE. Since nanomolar quantities ofL-742,395 failed 
to label monocytes if applied to intact cells,  but did label 
ICE active sites if applied to ultrathin frozen sections of the 
monocytes, it appears that the ultrathin sectioning process 
permits the peptidyl ICE inhibitor to label subcellular sites 
normally not accessible  in intact monocytes. 
IL-1~ Is Localized on the Cell Membrane during Cytokine 
Secretion.  The localization of both p20 ICE epitopes and 
ICE  active sites  on the  cell surface strongly suggests  that 
IL-113 might  interact with  the  monocyte cell membrane Figure 3.  ImmunoEM localization oflCEJD3 and propiece (p11)  epitopes in cryosections of unstimulated (A and B) or stimulated (C) human mono- 
cytes.  (A) As with HKSA-activated monocytes, JD3 epitopes are localized on the external surfaces of the cell membrane (arrowheads), on microvilli (M), 
within pinocytic vacuoles (V), and in the cytoplasmic ground substance (arrows). The nucleus (N)  and ER. are unlabeled. (B) ImmunoEM micrograph of 
a cell similar to that in A illustrating the staining ofJD3 epitopes on the surface (arrows)  ofa microvillus (M), and in the cytoplasmic ground substance (ar- 
rowheads) exclusive of the Elk.  (C)  Immunolocalization of ICE propiece (p11)  epitopes by I34-47 IgG is confined to the cytoplasmic ground substance 
(arrowheads) in HKSA-stimulated human monocytes. Unlike JD3, prolCE labeling is not detectable on the outer surface of the cell membrane (arrows). 
Bars for A-C, 0.2 Izm. 
1452  IL-l{3 Convertase Is Localized on the Cell Membrane by Immuno-Electron Microscopy Table 2.  Immunofluorescent  Microscopic Detection of ICE and 
IL- 1~ in Stimulated Versus Unstimulated Monocytes 
Antibody 
Percent positive  Percent 
unstimulated  positive stimulated 
monocytes  monocytes 
Anti-ICE  (JD3)  98  95 
Anti-IL-  113 
(197-215)  2  98 
Coverslip cultures of HKSA-stimulated or unstimulated human mono- 
cytes were fixed as described  (18), permeabilized  with 0.1% Triton X-100 
in PBS, immunostained with JD3 anti-ICE IgG or with an antibody 
against mature IL-1~3, and bound IgG detected with FITC-conjugated 
goat anti-rabbit IgG. Data shown are the percentage  ofimmunofluores- 
cent-positive monocytes observed (sample sizes ranged from 500--800 
cells per group). 
during cytokine secretion. Since IL-113 was not detected at 
the monocyte cell membrane after conventional endotoxin 
stimulation (3), we sought to determine the location of the 
native  ICE  substrate  prolL-l[3  and  its  cleavage product, 
mature IL-113, under conditions in which the rate of IL-113 
secretion is maximal (Table 3). Monocytes respond to very 
low LPS concentrations by synthesizing, but not secreting, 
proIL-1 [3 (16, 23). Rapid processing and secretion of IL-113 
can then be initiated with a high dose of LPS or HKSA, 
even in the presence of cycloheximide, indicating that the 
release of mature IL-l[3 occurs by conversion of prolL-l[3 
from a preexisting pool (16).  This protocol thus allows a 
direct comparison of the distribution of mature IL-113 and 
prolL-1 [3 in nonsecreting and secreting monocytes. Human 
monocytes were fixed after both the priming and secretory 
phases of stimulation,  and immunoEM was performed on 
ultrathin cryosections with an antibody against mature IL-113 
(amino  acid residues  197-215).  Significant IL-113 staining 
was observed on the cell surface during the secretory phase 
of stimulation  (Fig.  5 A), while labeling was  absent from 
the cell surface but present in the cytoplasmic matrix dur- 
ing the priming phase when no IL-113 is released (Fig.  5 B 
and  Table  3).  Furthermore,  another  antibody  directed 
against  prolL-l[3 NH2-terminal amino acid residues 3-21 
(15)  detected proIL-l[3 epitopes on the cell surface of se- 
creting (Fig.  5  C)  but not primed  (Fig.  5 D)  monocytes. 
The  observation  that  prolL-l[3  or  the  propiece  can  be 
colocalized to the same subcellular site as active ICE itself 
lends further credence to our data concerning localization 
of ICE on the cell membrane. These data, however, do not 
indicate whether such  cell surface-associated (presumably 
secreted) proIL-l~3 epitopes represent intact or fragmented 
IL-l[3 precursor. 
To determine if the cleaved propiece of prolL-l[3 could 
be secreted from monocytes, polyclonal antisera were pre- 
pared to the COOH-terminal neo-epitope generated upon 
cleavage of prolL-l[3 by ICE.  The specificity of the anti- 
body was  confirmed by immunoprecipitation and immu- 
noblotting  of purified  prolL-l[3,  ICE-cleaved  prolL-l[3, 
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and  mature  IL-l[3.  Antibody 502T  did not  detect intact 
prolL-l[3 or mature IL-113 after immunoprecipitation and 
Western blotting.  Upon  cleavage of prolL-l[3 with  ICE, 
however, 502T quantitatively immunoprecipitated a 14.5- 
kD  protein  corresponding  to  the  expected  size  of the 
prolL-l[3  propiece.  Secretion  of the  propiece  was  con- 
firmed by demonstrating  the  presence  of this  protein  in 
culture  supernatants  of LPS  stimulated  monocytes along 
with mature IL-113; 502T did not detect the 14.5-kD pro- 
piece in  the  corresponding cells  (not shown).  Treatment 
with the ICE inhibitor L-709,049 abolished the production 
of  both the propiece and the mature IL-113 with a concom- 
itant elevation in prolL-l[3 secretion (Fig.  6). The amount 
of propiece that was secreted appeared to be similar to the 
amount of secreted mature IL-113. This is based on a spike 
recovery experiment that used an  amount of ICE-gener- 
ated  IL-l[3 propiece equivalent to the amount of mature 
IL-l[3 found in the culture supernatants.  The data suggest 
that prolL-1 [3 is proteolytically processed as it is transported 
across the monocyte cell membrane during IL-1 [3 secretion 
with a near quantitative release ofpropiece and mature IL-1 [3. 
Discussion 
We have used immunoEM to localize both ICE and IL-113 
in  human  peripheral  blood monocytes to  further under- 
stand the role that ICE plays in the process of IL-l[3 secre- 
tion. Immunolocalization of ICE was accomplished using a 
polyclonal antibody recognizing epitopes common to the 
p20  subunit of active ICE  and inactive p45  ICE  (12),  as 
well as an antipeptide antibody directed towards a sequence 
unique to the p45 ICE propiece. Immunolabeling was ob- 
served on  the  cell surface membrane  using  the  antibody 
that recognized p20 and p45 ICE. Plasma membrane stain- 
ing,  however, was  not  detected with  the  ICE  propiece- 
specific antibody. Since the propiece is absent from active 
ICE, this data suggests active ICE, but not proICE, is asso- 
ciated with the monocyte plasma membrane.  In  contrast, 
both immunoprobes detected ICE epitopes in the ground 
substance of the  cytoplasm, outside of the Elk and Golgi 
apparatus.  This result is consistent with previous biochemi- 
cal observations that ICE is found primarily in the mono- 
cyte cytosol (12). The specificity of the technique was con- 
firmed  by  demonstrating  that  labeling  was  blocked  by 
absorption  of the  primary antibody with purified human 
rICE  for anti-p20  or with  a  specific peptide for antipro- 
piece IgG. Staining was also abolished by substituting non- 
immune IgG for primary antibody in each case. 
To confirm and extend the immunoEM localization of 
p20 ICE protein in monocytes, we also developed a method 
to label  the  active site  of ICE  with  a specific  biotinylated 
probe. Intact human monocytes were activated with HKSA 
and  then treated with  L-742,395  (22).  After fixation and 
cryosectioning of the cells, a significant  amount of label was 
found to be associated with the plasma membrane, as well 
as with the  cytosolic ground substance.  This labeling ap- 
peared specific and significant since staining did not occur 
in the presence of the nonbiotinylated but otherwise iden- Figure 4.  Immunoelectron micrographs illustrating ICE active site labeling in HKSA-stimulated human monocytes. (A) Monocyte that was treated with 
18 ~M L-742,395 before fixation and cryosectioning exhibits ICE active site labeling on the outer surface of the cell membrane (arrowheads) and within 
the cytoplasmic ground substance (arrows). This cell is from a culture that secreted 0.75 ng IL-1[3/10  s cells/ml into the medium (representing a 75% inhi- 
bition of IL-113 secretion). (13) Staining of active ICE with 500 nM L-742,395 after fixation and cryosectioning. ICE active sites are localized on the outer 
surfaces of the cell membrane (arrowheads), in pinocytic vacuoles (V), and within the cytoplasmic ground substance (arrows). (C) Active-site labeling of an 
activated monocyte cryosection with 5 nM biotinyl-irreversible ICE inhibitor. Although there is reduced staining, the patterns of active ICE labeling are 
similar to those observed in (B).  (D)  ICE active site labeling of a cryosection with 500 nM biotinyl-irreversible ICE inhibitor in the presence of a 400- 
fold molar excess of unlabeled L-709,049 added as a competitor. Most ICE active site labeling as illustrated in B is absent under these conditions. Bars for 
A-D,  0.2 ~m. 
1454  IL-I~ Convertase Is Localized on the Cell Membrane by Immuno-Electron Microscopy Table 3.  IL- 118 Secretion after the Staged Stimulation of Human 
Monocytes 
Stimulus  IL-113 secretion w 
ng /ml 
LPS*  0.18 
LPS +  HKSA*  2.60 
RPMI  0.0 
*Elutriated human monocytes (5 ￿  10S/ml) were stimulated with LPS 
(50 pg/ml) for 6 h. 
*Cells (5  ￿  105/ml) were activated with LPS (50 pg/ml) for 4 h, fol- 
lowed by 106 CFU HKSA for an additional 2 h. 
w IL-113 was detected in culture supernatams by ELISA at~er a total of 6 h 
stimulation. 
tical ICE inhibitor L-743,066.  Furthermore,  L-742,395  la- 
beled the cell surface membrane at micromolar concentra- 
tions but not at nanomolar concentrations when applied to 
whole ceils.  These results correlate directly with the quan- 
tities of L-742,395  required for inhibition  of IL-113 secre- 
tion from these same cells. The correlation between labeling 
of the cell membrane with an ICE inhibitor and concomi- 
tant inhibition of IL-113 secretion strongly suggests that ac- 
tive ICE is localized to the plasma membrane. 
Although  the  results  of the  whole-cell labeling experi- 
ment  were  highly  significant,  they  were  limited  because 
micromolar quantities of L-742,395 were required to label 
the monocytes, suggesting that a portion of the intracellular 
ICE  pool  might  not  be  accessible  to  this  compound.  A 
postsectioning method was therefore developed for label- 
ing the ICE active site.  This procedure involved detection 
of the biotinyated compound on ultrathin  cryosections of 
fixed monocytes with an avidin-based amplification system. 
Labeling was performed directly on the  sections  to  allow 
access  of the ICE probes to all sectioned intracellular com- 
partments. Intact monocytes were initially treated with the 
reversible ICE inhibitor L-709,049  in vitro to protect the 
active site before fixation,  and they were then washed  to 
deprotect the  enzyme and remove any potential competi- 
tor.  Subcellular sites  of active ICE that were rendered ac- 
cessible by the ultrathin  sectioning process were then de- 
tected  by labeling  the  cryosections  with  the  biotinylated 
ICE inhibitor.  Under these conditions,  active ICE was lo- 
calized to both the cell surface membrane and the cytoplas- 
mic ground  substance  using nanomolar quantities  of ICE 
inhibitor.  Similar staining patterns were observed in stim- 
ulated  or unstimulated monocytes. This labeling could be 
inhibited with an excess of the nonbiotinylated parent com- 
pound (a peptidyl acyl-oxy-methyl-ketone) or with the re- 
versible ICE inhibitor L-709,049  (a peptidyl aldehyde). The 
latter result is particularly significant since these inhibitors 
share  a  tetrapeptide  sequence  (YVAD)  required  for  ICE 
recognition, but they inhibit the enzyme by distinct chem- 
ical  mechanisms  (11,  22).  The  tetrapeptide  sequence  is  a 
key determinant of inhibitor selectivity for ICE, and it sug- 
gests that the labeling occurs through  specific recognition 
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as opposed to nonspecific alkylating properties of this com- 
pound. Similarly, the specificity of these inhibitors for ICE 
should preclude labeling of ICE homologues since the se- 
lectivity of YVAD is  104 greater for ICE than for CPP32, 
an  ICE-like  protease  recently  linked  to  apoptosis  (23a). 
Thus, the L-742,395  localized on monocyte sections most 
likely represents labeling of ICE. 
The  fact  that  ICE  can  be  specifically detected  on  the 
monocyte plasma membrane by these methods is an indica- 
tor  of the  high  resolution  and  sensitivity  of our  immu- 
noEM technique.  The stability of the interaction between 
ICE and the plasma membrane, as well as the quantity of 
cell membrane-associated ICE observed, however,  cannot 
be ascertained from the present data.  In addition,  ICE ac- 
tivity has not been unequivocally demonstrated in associa- 
tion  with  membrane or particulate  fractions from human 
monocytes  by  subcellular  fractionation  and  biochemical 
methods. Indeed active ICE, as defined by the presence of 
p20/pl0  subunits,  has  not been  detectable in  monocytes, 
where  >99%  of the  observable ICE is the p45  species of 
ICE (12).  There are several possible reasons for this appar- 
ent  discrepancy.  First,  immunoEM  localization  was  per- 
formed on monocytes cross-linked under conditions known 
to preserve native cell structure and antigenicity as much as 
possible, thus  avoiding possible damage and/or loss  of ac- 
tive ICE that might occur during cellular lysis and fraction- 
ation  (3,  21).  Second,  the high resolution  of immunoEM 
enables  specific labeling of individual  ICE  active sites  on 
relatively small amounts  of membrane directly within  the 
complex  intracellular  ultrastructure.  This  allows  one  to 
readily distinguish  between  active-ICE label localized  on 
the cell membrane from ICE epitopes present in the cyto- 
solic matrix. Third, the tremendous amplification potential 
of the  biotin/avidin/antiavidin  detection  system  permits 
detection of small quantities of a given epitope that is ordi- 
narily not detectable by more conventional immunolabel- 
ing  methods  (24,  25).  Given  the  sensitivity  of the  tech- 
niques  that  were  used,  the  evidence  suggests  that  ICE 
activity levels  are  low  and  are  under  strict  regulation  in 
monocytes. 
The localization of ICE to the outer surface of the plas- 
malemma by two  distinct  methods  strongly  suggests  that 
IL-113 secretion occurs through the plasma membrane, and 
that processing occurs  on or in  close association with the 
lipid bilayer. To extend this hypothesis, we sought to de- 
termine the location of the native ICE substrate, prolL-l[3, 
and  its  cleavage  product,  mature  IL-I~.  To  accomplish 
this, we compared the subcellular localization of IL-113 be- 
tween monocytes that had synthesized prolL-l[3, but either 
were actively secreting mature IL-113 or not (16).  Localiza- 
tion of prolL-l[3 was accomplished by the use of an anti- 
peptide  antibody directed  towards  an  NH2-terminal pro- 
domain epitope  (1,  3,  15).  A  second antibody specific for 
the COOH-terminal domain was used to localize both ma- 
ture and prolL-1[3 (1).  In primed monocytes that were not 
secreting  IL-I~,  both  prodomain  and  COOH-terminal 
IL-113  epitopes  were  located  exclusively in  the  cytosolic 
ground  substance.  Subsequent  treatment  of the  cells  with Figure 5.  Mature (A and B) and precursor (C and D) IL-113 epitopes are localized on intact cell surface membranes of  activated human blood monocytes 
during the secretory (A and C), but not in the priming phases (B and D) of the staged secretory process. Arrows in all panels delineate intact continuous 
cell surface membranes that show no evidence of apoptosis. (A and B) Mature IL-113 (amino acids  197-215)  is localized on the cell surface  membrane 
(large arrowheads) and in the cytoplasmic matrix (small arrowheads) of IL-113-secreting cells (A), and is only observed in the cytoplasm (small arrowheads) of 
primed nonsecreting cells, exclusive of the cell membrane (B).  (C and D) Similarly, IL-1~3 precursor (amino acids 3-21) is detected on the cell surface 
membrane (large arrowheads) and in the cytoplasmic ground substance (small arrowheads) of cells secreting IL-113 (C), but is restricted to the cytoplasm (small 
arrowheads) in primed cells (D). Bars for A-D,  200 nm. 
1456  IL-113  Convertase Is Localized on the Cell Membrane by Immuno-Electron Microscopy Figure 6.  Identification of ICE-dependent prolL-113 cleavage products 
in supernatants of HKSA-stimulated human monocytes. IL-113 secretion 
products were identified by sequential immunoprecipitation and Western 
blotting with antibody 502T (lanes I-5) or with a rabbit anti-human IL- 
113 polyclonal antibody (lanes 6 and  7) (16). Lane 1, 60 ng of ICE-di- 
gested prolL-113 standard, no immunoprecipitation; lane 2, spike recov- 
ery of 60 ng of ICE-digested prolL-113 in unstimulated monocyte cell 
culture supematant; lane 3, unstimulated monocyte cell culture supema- 
tant; lanes 4 and 6, cell culture supematant from LPS-stimulated mono- 
cytes; lanes 5 and 7, cell culture supematant from LPS-treated monocytes 
in the presence of 100 p,M L-709,049. The amount of IL-113 immuno- 
precipitated from the culture was 60 ng, based on determination of se- 
creted IL-113 by ELISA. 
HKSA to induce high rates of IL-l[3 secretion resulted in a 
mobilization of IL-113 to  the plasma membrane  detectable 
with  prodomain  or  mature  domain  IL-113  antibodies.  In 
this system,  the bulk of secreted IL-113 is the mature pro- 
cessed  form  (16).  That  the  prodomain  of IL-113  is  also 
found  associated with  the  plasma membrane  suggests  that 
this domain is also secreted. 
Previous  experiments  have  suggested  that  the  propiece 
of prolL-l[3 is both cell-associated and secreted from stim- 
ulated monocytes (26). This study, however, did not ascer- 
tain whether the release of the propiece was related to ICE 
activity and/or IL-113 secretion. We  have  now detected a 
processed prolL-l[3 propiece in the medium using antibod- 
ies directed against the Asp-COOH-containing neo-epitope 
generated by ICE cleavage at the Asp116-Ala  t17 position of 
prolL-l[3. Treatment of monocytes with the ICE inhibitor 
L-709,049  resulted in inhibition of mature IL-113 (11)  and 
IL-113 propiece secretion. Taken together with our immu- 
noEM data, these results indicate that prolL-l[3 is probably 
processed close to the external surface of the plasma mem- 
brane  during  secretion,  resulting in  the  release  of mature 
IL-l[3 and the IL-l[3 propiece (Fig. 7). 
Our  observations  raise  the  possibility that  IL-113  is  se- 
creted via a  nonclassical mechanism.  We propose a  model 
of  directional  IL-113  processing  and  transport  directly 
through the plasma membrane  (Fig. 7). There is some evi- 
dence  to  suggest  that  ICE  is  necessary  and  sufficient  for 
secretion  of IL-113:  coexpression of prolL-l[3 and  ICE  is 
required for  the  release of processed IL-113 in both  trans- 
fected COS  cells and baculovirus-infected insect cells (27, 
28). The requirement for ICE catalytic activity in IL-113 se- 
cretion is not clear.  In LPS-stimulated human  monocytes, 
inhibition of IL-113 processing with low molecular weight 
ICE inhbitors such as L-709,049  does not block secretion; 
there  is a  quantitative  release  of prolL-l[3 instead.  In  Sf9 
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Figure 7.  Transmembrane model of directional processing and transport 
of prolL-113 by ICE. ProlCE  present in the cytoplasm is proteolytically 
activated, assembled,  and inserted into the cell membrane as a hypotheti- 
cal multimeric ICE pore  complex in association with as yet unknown 
transmembrane accessory  proteins(?=unknown  proteins). ICE pores con- 
sist of active ICE p20/pl0 heterodimers arranged with their active sites 
(SH) protruding through the glycocalyx  coating the outer membrane sur- 
face. Properly oriented prolL-113 may only enter the ICE pore through 
the cytoplasmic  face of the cell membrane. ProlL-113  is proteolytically ac- 
tivated in the absence (-) of an ICE inhibitor, resulting in the secretion 
of mature IL-113 plus the IL-113 propiece. Intact prolL-113 is secreted in 
the presence (+) of ICE inhibitor. Like prolL-113, ICE inhibitors may 
gain access to the ICE pore complex solely through openings on the cy- 
toplasmic face of the plasmalemma. This hypothesis suggests that to in- 
hibit ICE, sufficient  cytoplasmic  concentrations ofpeptidyl ICE inhibitors 
are required to interact with membrane-associated ICE in intact mono- 
cytes. 
cells infected with baculovirus coexpressing proIL-l[3, crm 
A, ICE, and IL-1 [3, however, secretion is completely blocked 
(28).  This suggests that the interaction of ICE with a  high 
affinity, large molecular weight inhibitor is capable of steri- 
cally blocking IL-1 [3  secretion.  Similarly, the  observation 
that  both  IL-I[3  and  IL-lct secretion  are  significantly re- 
duced in  mice  that  have  had  the  ICE  gene  knocked  out 
supports the hypothesis that ICE may be required for secre- 
tion,  but  not  processing,  of IL-lct since  proIL-10~  is  not 
cleaved by ICE (29). This data further supports the hypoth- 
esis that ICE may be associated with IL-1  secretion that is 
independent  of its  proteolytic  activity.  Our  data  suggest 
that cytoplasmic prolCE  is proteolytically cleaved to  form 
active  p20/pl0  heterodimer  in  association  with  the  cell 
membrane.  Because  ICE  has  no  known  structural  motifs 
associated with membrane  localization, a  mechanism must 
exist to localize the protein to  the plasma membrane.  We 
propose  that  ICE  multimers are arranged into heteromeric 
pore  complexes perhaps  associated  with  as  yet  unknown 
transmembrane proteins. ICE would be oriented such that 
its p20/pl0  heterodimers are arranged with their active sites 
protruding through the glycocalyx  coating the outer mem- 
brane surface.  Access of enzyme by substrate would occur 
through  the  cytoplasmic face of the  cell membrane.  Since 
both prolL-l[3 and the natural inhibitor crmA (30)  do not 
serve  as  ICE  substrates  or  inhibitors,  respectively,  when 
supplied  extracellularly to  cultured  monocytes  (data  not 
shown), we think that the active site of ICE is functionally 
masked to  extracellular macromolecules. The  ABC family of transporters  may provide a paradigm for the association 
of ICE with transmembrane  pore complexes.  Similar pro- 
teins are involved in the secretion of both small hormones 
like  yeast A  factor  (31,  32)  or very large proteins  such  as 
hemolysin A in Escherichia coti (reviewed in reference 33). 
There  is a  growing current literature  documenting that 
ICE  is  a  member  of a  family  of cysteine  proteases  that 
cleave substrates  at Asp Pl,  which may be associated with 
apoptosis  in  several  systems  (34-40).  Overexpression  of 
ICE has  been shown  to result  in apoptosis,  a  process  that 
may ultimately lead  to the  release  of intracellular  compo- 
nents in cell culture  (37,  39, 40).  Similarly,  several reports 
have associated the onset of apoptosis with IL-113 secretion 
from monocytes (13,  14).  Induction  of apoptosis  in LPS- 
treated murine macrophages by ATP treatment resulted in 
the  release  of processed  IL-113,  and  intracellular  enzymes 
such  as  lactate  dehydrogenase  (13,  14).  It is  important  to 
note, however, that apoptosis was observed in ATP-treated 
murine macrophages derived from ICE-deficient mice.  In- 
terestingly,  the  expected  release  of prolL-l~  from  these 
cells  failed to occur after  apoptosis  (41).  The  data  suggest 
that  ICE itself is not necessary for the  onset  of apoptosis, 
and that  IL-113  secretion is an active process  that  requires 
ICE.  Apoptosis  itself is  probably  driven  by other  distinct 
ICE-like  proteases  under  tight  regulatory  control,  whose 
activity  is  unrelated  to  IL-113  secretion  (34,  36,  39,  42). 
The ultrastructural characteristics of actively secreting mono- 
cytes  discerned  from  the  high  resolution  frozen  sections 
used  in  this  study support  this  point  as  well.  Secretion  of 
IL-113  occurs from monocytes with  no demonstrable  evi- 
dence of the membrane and nuclear perturbations  that oc- 
cur during apoptosis (reviewed in references 43 and 44).  In 
particular,  the lipid bilayer of the  cell membrane appeared 
totally  intact  and  continuous.  Microvilli  and  lamellipodia 
exhibited  a  normal  morphology and  did  not  exhibit  any 
signs  of blebbing.  The  nuclear  chromatin  was  dispersed, 
and  it  lacked  signs  of margination  and  condensation.  We 
conclude that IL-113 secretion may occur in stimulated hu- 
man PBMC by a novel secretory mechanism that does not 
involve apoptosis, cell death, or surface membrane lysis. 
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